Dave Ricks, Eli Lilly

Eli Lil­ly buys a Roche dis­card in $1.1B Der­mi­ra buy­out. Can they go toe-to-toe with the heavy­weight chal­lenger Dupix­ent?

Eli Lil­ly thinks it has found a bet­ter way to tack­le the atopic der­mati­tis mar­ket now be­ing dom­i­nat­ed by Dupix­ent.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.